We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Oncolab Exhibits Pioneering AMAS Cancer Test at AACC

By LabMedica International staff writers
Posted on 29 Jul 2014
Print article
Image: The AMAS test by Oncolab is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility (Photo courtesy of Oncolab).
Image: The AMAS test by Oncolab is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility (Photo courtesy of Oncolab).
The Oncolab (Boston, MA, USA) laboratory-developed AMAS cancer test is making its AACC debut at this year's 2014 conference. To date, the test, which is a serum-based in vitro immunoassay, has been run for over 60,000 patients and appears to be an emerging tool in the fight against cancer recurrence as well as detection.

There are an estimated 17 million cancer survivors in the US alone, hence there is a race to develop better technologies for identifying whether a cancer has begun to recur, and if so at what rate. There is a clear trend towards the use of immunoassays in cancer diagnostics, as immunotherapy for treatment. The AMAS test fits into these trends by measuring the level of a specific antibody, Anti-Malignin Antibody, which is thought to be produced by the body's immune system in response to nearly all forms of cancer.

Most other cancer immunoassays measure circulating cancer antigens, which become elevated later than the antibody measured in the AMAS test. Therefore, the AMAS Test helps to pick up recurrence at an early stage when levels of anti-malignin antibody are often elevated early in the occurrence and recurrence of cancer. This is a distinctive capability—false positive and false negative rates are under 10%. While the AMAS test does provide guidance to the likely location of the cancer, new high-resolution imaging techniques, more location-specific cancer tests, and clinical signs help the clinician provide patients with a fuller picture of the disease.

Currently, Oncolab provides the test via submission of samples to its CLIA-certified laboratory in Boston. Serum samples must be shipped via overnight courier, using a standardized shipping container and tubes provided at no cost by Oncolab, dry ice obtained at the lab while doing the blood draw, and separation to serum. The test is approved by the US Food and Drug Administration (FDA) and reimbursed by Medicare.

Today, the majority of samples being run are drawn in the US and Canada; overseas labs can also ship samples and are urged to contact Oncolab to get a technical and business relationship started.

The AMAS test, by Oncolab, is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility in Boston. The test is able to detect early cases of cancer recurrence, a major concern for 17 million Americans. This year is the company's debut at the AACC (American Association for Clinical Chemistry), being held in Chicago - booth #4051.

Related Links:

Oncolab


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.